BioSpace News Archive

Series B financing to support ongoing Phase 1/2a clinical trial of Tegavivint in desmoid tumors and initiation of clinical trials in acute myeloid leukemia, non-small cell lung cancer and pediatric cancers

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 41 st Annual Cowen Health Care Conference on Monday, March 1, 2021 from 12:20 p.m. to 12:50 p.m. ET.

Henry Schein One, a joint venture of Henry Schein, Inc., and Internet Brands, has announced that Mike Baird will assume the role of Chief Executive Officer, leading all aspects of Henry Schein One’s business.

SONN-1010, fully human IL-12 configured using F H AB platform, Non-Human Primate study informs pharmacokinetic profile Launch of At-The-Market Offering Program for up to $15,875,000 of common stock

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18, 2021, at 3:00p.m. Eastern Time.

Nikon Instruments Inc., innovator of advanced microscope systems, today announced the release of the ECLIPSE Si biological microscope , with intelligent time-saving features, an automatic shut-off mode, and an ergonomic design to reduce physical strain that can occur with prolonged microscope use.

AliveCor, the leader in AI-based personal ECG technology and provider of enterprise cardiology solutions, today announced a new collaboration with AstraZeneca

New module utilizes state-of-the-art deep learning (DL) algorithms combined with classic computer vision methods to create a 3D model of the coronary arteries to better visualize artery structure and reduce procedural risks to patients

Baxter International Inc., a leading global medical products company, announced that its Board of Directors has declared a quarterly cash dividend of $0.245 per share of common stock.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, a critical step in the company’s ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.